Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trialAlbert M. Maguire, Jean Bennett, Jessica I. W. Morgan et al.|The Lancet|2009Cited by 857
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector AdministrationFrancesca Simonelli, Alberto Auricchio, Albert M. Maguire et al.|Molecular Therapy|2009Cited by 551
AAV2 Gene Therapy Readministration in Three Adults with Congenital BlindnessJean Bennett, Albert M. Maguire, Manzar Ashtari et al.|Science Translational Medicine|2012Cited by 390
Effective delivery of large genes to the retina by dual AAV vectorsIvana Trapani, Alberto Auricchio|EMBO Molecular Medicine|2013Cited by 258
Triple Vectors Expand AAV Transfer Capacity in the RetinaAndrea Maddalena, Alberto Auricchio|Molecular Therapy|2017Cited by 124